Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Orthodontics will grow, but the rest of it I think has enormous growth coming and we’re really excited about it |
| Even in the difficult revenue environment of 2023, personalized healthcare was a positive outlier, if you flip to Slide 9, delivering double-digit growth year-over-year, and we expect this trend to continue |
| And with all of that said, industrial hung in there better than healthcare last year |
| Defense and aerospace remain strong |
| And finally, with stable revenue performance, expanded gross margins and carefully managed OpEx at reduced levels from 2023, we're committed to deliver positive adjusted EBITDA performance and operating cash flow for 2024 |
| And the closer you get to specialized equipment like semiconductor equipment manufacturer, very strong for us |
| Any volume leverage on revenue upside would further enhance this performance |
| So, that - qualitatively that's - it's in those three buckets and that's why you'll see the lift in both gross and EBITDA margins, even in a flat sales environment |
| Our insourcing supply chain and restructuring work to date has provided a strong foundation for gross margin improvement, and we expect that to continue even in a static sales environment |
| This benefit has been enabled by the improving economics of 3D printing, enabled by increased printer size, speed, and reliability |
| While this is still a highly developmental area, and undoubtedly some avenues will advance more quickly than others, we continue to believe that regenerative medicine offers tremendous value creation in the future |
| In total, this represents collaborative contracts now with two of the top four largest pharmaceutical companies in the world, and an impressive pipeline of future opportunities ahead |
| To this end, we've gained significant momentum and validation of our technology, and I'm pleased to announce that before the end of last year, Systemic Bio successfully closed their second contract with another large pharmaceutical company |
| We believe Systemic’s h-VIOS platform has the potential to dramatically improve the drug discovery and development timeline, particularly important considering market research indicates that nine out of 10 drugs fail in clinical trials, leading to an average of $2.6 billion invested by pharma companies per drug approved, with over a 12-year time horizon to establish FDA approval for each drug introduced to the market |
| Non-GAAP gross margin for the year was 41.1%, a 130 basis-point improvement over the prior year, and primarily driven by favorable mix, operating efficiencies, and the positive impact of price increases to offset inflationary pressures |
| It's important to note that while the favorable impact of mix is more indicative of the associated short-term pressures on customer CapEx deployments for printers, they're increasingly encouraged by our insourcing and efficiency efforts and the positive impact we expect them to drive on longer-term margin expansion |
| At almost $500 million of revenue in 2023, we're one of the largest companies in the industry, with strong gross margins that continue to improve even in this difficult economic climate |
| Our R&D investments support the broadest range of additive technologies in the entire industry, bringing together metal and polymer hardware platforms and an exceptional materials portfolio with intelligent cloud-based software to deliver targeted application solutions to key customers around the world |
| Clearly, there's a really nice ability to generate cash from that working capital this year, and we're working that aggressively |
| Coupled with our technology roadmap for new product introduction expected throughout 2024 and beyond, it's reasonable to expect continued improvement in gross margin performance on a year-over-year basis going forward |
| No one in the world is better positioned than we are to bring these solutions to the market, creating value for all of our stakeholders |
| In the short term, we have the flexibility to adapt to economic volatility by taking out costs and to do so without stifling future growth investments needed to serve that $80 billion addressable market in the years ahead, endorsed by a strong balance sheet, with a healthy cash reserve, providing headroom to execute on a strategy that delivers substantial value creation for the horizon ahead |
| With the addressable denture market expected to exceed $2 billion by 2028, this presents a tremendous opportunity for our Jetted Denture Solution |
| And again, I'd like to think we'll do better than that, but it’s - we try to be realistic about timing because I do think you'll see a big hit in the first half, which is good, but a lot of the benefits don't start flowing through until the second half |
| As a starting point, you just heard me talk about our strong balance sheet |
| As you've heard from me multiple times over the last few years, our regenerative medicine initiative is unparalleled and a strategic differentiator, with technology that may not only deliver transformational growth and shareholder value for our company, but importantly, profoundly change the future of healthcare |
| Setting this aside, expectations for 2024 for reductions in OpEx and continued improvement in gross margin performance, both of which lead to improved EBITDA realization |
| This led to greater efficiencies for the business throughout 2023 as reflected in our rising gross margins, and we expect to unlock even more benefits going forward |
| With healthy cash reserves and an opportunity to drive considerable improvements in working capital through inventory reduction in the year ahead, we have an ability to be very methodical and deliberate in our restructuring efforts, balancing the need for improved operating efficiencies with support for critical R&D investments needed to deliver the growth we see ahead |
| The transaction strengthened our overall balance sheet, with the extinguishment of nearly 30% of the outstanding maturity, while leaving healthy cash reserves to invest in future growth to fund core operations and strategic optionality |
| Statement |
|---|
| Without question, 2023 proved to be a challenging year, and it all centered on revenue, which remained under significant pressure all year long |
| Healthcare solutions reported fourth quarter revenues of $51 million, down approximately 16% from prior year and across most markets |
| Healthcare solutions delivered full-year revenues of $213 million, declining approximately 18% from the prior year |
| From a segment perspective, industrial solutions reported fourth quarter revenues of approximately $64 million, a 12% decline from prior year |
| Year-over-year results were primarily impacted by a headwind in our dental orthodontics business, further amplified by broader macro weakness pressuring most other markets, which was most accurately reflected in printer sales |
| For the full year 2023, we reported consolidated revenues of $488 million, down 9% from the prior year |
| And to aid with modeling, we expect a seasonally soft start to the first quarter, with revenues down sequentially and year-over-year |
| From a segment perspective, revenues in industrial solutions mostly held firm at $275 million, with full year performance declining about 1%, despite a tougher economic backdrop |
| In the end, our full year dental orthodontics business declined 39% |
| For the full year 2023, adjusted EBITDA of negative $24.5 million declined from the prior year by $18.7 million |
| Far and away the most significant impact on our year-over-year revenue decline was attributed to our dental orthodontics business |
| To be clear, this was a delay in placing orders, with very few cancellations as our customers remain committed to additive manufacturing as incremental capacity is needed and new products are introduced |
| Shifting to our fourth quarter performance on Slide 18, we reported consolidated revenues of $114.8 million, declining approximately 14% from the fourth quarter of 2022 |
| Do we come up with an actual number for Greg? We don't normally break that out, but I can tell you, Greg, just qualitatively, our shortfall in revenue was hardware driven, not materials and services |
| You'll see a slightly negative - my guess is a slightly negative free cash flow as we invest CapEx, and we'll update you on that throughout the year |
| I can tell you qualitatively, Greg, the equipment was really tough last year with CapEx spending being down |
| This pressure built significantly in 2023 as demand in the orthodontics space tumbled and inventory spiked |
| Making matters worse from a demand perspective, last year was a broad-based macroeconomic and geopolitical uncertainties, created in part by the rapid rise in interest rates used in an effort to dampen inflation |
| For the fourth quarter 2023, adjusted to EBITDA of negative $12.3 million declined in the prior year by $7.5 million, primarily driven by the same factors as noted above |
| That’s as much as I can tell you, but I truly don't believe there was any share loss, and I think it was strictly slow rolling purchase orders on our customers’ part by and large |
Please consider a small donation if you think this website provides you with relevant information